Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAN-3110
- Development stage
- Phase 1
- Lead developer
- Candel Therapeutics
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intratumoral
01
Overview
CAN-3110 is a first-in-class, replication-competent oncolytic herpes simplex virus type 1 (HSV-1) immunotherapy engineered for dual activity—direct oncolysis and immune activation—in a single therapeutic agent. Its activity is conditional upon the expression of Nestin in cancer cells, allowing selective targeting of tumor tissue while sparing normal cells. The drug is being developed primarily for recurrent high-grade glioma (rHGG), including glioblastoma and other malignant gliomas, with ongoing phase 1b clinical trials showing promising safety and survival data compared to historical controls after intratumoral injection. Preclinical studies are also exploring its potential in melanoma and other solid tumors[1][2][3][4][5][6][8].
- Other names
- CAN 3110CAN3110CAN-3110
02
Targets
TMEFF2NECTIN1 (Poliovirus receptor-related 1)
Beyond the preview
Go deeper on CAN-3110.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAN-3110.